Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
J Pain Res. 2014 Aug 20;7:505-14. doi: 10.2147/JPR.S67479. eCollection 2014.
The aim of this study was to find signs of progress in the pharmacotherapy of chronic pain over the past 35 years using scientometric analysis. The following scientometric indices were used: 1) popularity index, representing the share of articles on a specific drug(s) relative to all articles in the field of chronic pain; 2) index of change, representing the degree of growth in publications on a topic from one period to the next; 3) index of expectations, representing the ratio of the number of articles on a topic in the top 20 journals relative to the number of articles in all (>5,000) biomedical journals covered by PubMed; and 4) index of ultimate success, representing a publication outcome when a new drug takes the place of a common drug previously used for the same purpose. Publications on 55 drugs used in the treatment of chronic pain were assessed during seven 5-year periods, from 1979 to 2013. The rate of rise in the number of publications on chronic pain was exponential, with an increase of nearly ninefold from 2,346 articles over the 5-year period 1979-1983 to 21,095 articles in 2009-2013. However, despite this huge increase in publications, our scientometric analysis did not reveal signs of really successful drugs in this field. For the 2009-2013 period, the popularity index had a meaningful magnitude (from 0.5-2.8) for only 13 of 55 drugs. Five of them were opioids, including morphine, which had the highest index value of all drugs (2.8). None of the drugs had a high index of expectations in 2009-2013. The index of ultimate success was positive only with triptans in the relatively limited area of acute treatment of migraine. As a result, despite rapid growth in the number of publications, our scientometric analysis did not reveal signs of substantial progress in the field of pharmacotherapy for chronic pain.
本研究旨在通过科学计量学分析,寻找过去 35 年来慢性疼痛药物治疗进展的迹象。采用了以下科学计量学指标:1)流行指数,代表特定药物(或多种药物)的文章占慢性疼痛领域所有文章的比例;2)变化指数,代表某一主题的文献数量从一个时期到下一个时期的增长程度;3)期望指数,代表顶级 20 种期刊上关于某一主题的文章数量与 PubMed 收录的所有(>5000)生物医学期刊上的文章数量之比;4)最终成功指数,代表一种新药取代以前用于同一目的的常用药物时的出版结果。评估了 1979 年至 2013 年七个 5 年期间 55 种用于治疗慢性疼痛的药物的出版物。慢性疼痛出版物数量的增长呈指数增长,从 1979-1983 年的 5 年期间的 2346 篇增加到 2009-2013 年的 21095 篇,增加了近 9 倍。然而,尽管出版物数量大幅增加,我们的科学计量学分析并未发现该领域真正成功的药物的迹象。对于 2009-2013 年期间,55 种药物中仅有 13 种药物的流行指数具有显著的意义(0.5-2.8)。其中 5 种是阿片类药物,包括吗啡,它是所有药物中指数值最高的(2.8)。在 2009-2013 年期间,没有一种药物的期望指数较高。只有在偏头痛的急性治疗相对有限的领域中,曲普坦的最终成功指数为正。因此,尽管出版物数量迅速增长,但我们的科学计量学分析并未显示慢性疼痛药物治疗领域有实质性进展的迹象。